A phase II clinical and translational study of MK-0646 in patients with metastatic neuroendocrine tumors (NET)
Phase of Trial: Phase II
Latest Information Update: 24 Nov 2015
At a glance
- Drugs Dalotuzumab (Primary)
- Indications Neuroendocrine tumours
- Focus Therapeutic Use
- 15 Jan 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 30 Jan 2009 Trial centres updated from ClinicalTrials.gov record.
- 01 Oct 2008 Merck and Co added as a sponsor, based on information from ClinicalTrials.gov.